重链+轻链监测与多发性骨髓瘤患者临床结局相关
在463例新诊断多发性骨髓瘤患者巩固治疗后,比较电泳法与重链+轻链(HLC)免疫分析法判定缓解的一致性及临床影响。两法在部分缓解(79%一致)和完全缓解及以上(92%一致)相似,但在非常好的部分缓解(VGPR)患者中一致性仅45%。HLC缓解可进一步分层VGPR患者的中位无进展生存期(PFS),且HLC比值异常与多参数流式细胞术的一致性优于免疫固定电泳。
要点
- 在VGPR患者中电泳法与HLC法缓解判定一致性仅45%。
- 标准VGPR患者中位PFS为34.5个月,HLC缓解可进一步分层为PR、VGPR和≥CR,中位PFS分别为21.3、28.9个月和未达到,P<0.001。
- HLC配对抑制见于38%患者,与较短PFS相关(30.6个月 vs 未达到,P<0.001)。
核心结论
- HLC监测可补充电泳评估在达到VGPR患者中的不足。
- HLC缓解的预后意义可能部分取决于患者免疫系统恢复能力,由HLC测量正常化判定。
研究设计与样本
- 在463例新诊断多发性骨髓瘤患者巩固治疗后,比较电泳法与重链+轻链(HLC)免疫分析法判定缓解的一致性和临床影响。
主要发现
- 两法在部分缓解(PR)患者中一致率为79%,在完全缓解及以上(≥CR)患者中为92%,但在非常好的部分缓解(VGPR)患者中一致性仅45%。
- 标准VGPR患者中位无进展生存期(PFS)为34.5个月;HLC缓解将VGPR患者进一步分层为PR、VGPR和≥CR,中位PFS分别为21.3、28.9个月和未达到,P<0.001。
- 异常HLC比值与多参数流式细胞术(灵敏度10^-4)的一致性优于免疫固定电泳(阳性率分别为37%和34% vs 62%)。
- HLC配对抑制见于38%患者,与较短PFS相关(30.6个月 vs 未达到,P<0.001)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Novel anti-myeloma agents have improved patient response rates, which are historically based on reductions of the M-protein. These methods can be inaccurate for quantifying M-proteins at low concentrations. We compared the consistency and clinical impact of response assignment by electrophoretic and heavy+light chain (HLC) immunoassays post-consolidation in 463 newly diagnosed patients. The two methods gave similar assignments in patients with partial (PR; 79% agreement) or complete response (⩾CR; 92%). However, in patients achieving very good PR (VGPR) there was poor concordance between methods (45%). Median progression-free survival (PFS) for standard VGPR patients was 34.5 months; HLC responses stratified these patients further into PR, VGPR and ⩾CR, with median PFS of 21.3, 28.9 months and not reached, respectively; P<0.001. At this time, abnormal HLC ratios had better concordance with multiparametric flow cytometry (sensitivity 10-4) (37 and 34% positive, respectively), compared to immunofixation (62% positive). In addition, HLC-pair suppression was identified in 38% of patients and associated with shorter PFS (30.6 months vs not reached; P<0.001). We conclude that HLC monitoring could augment electrophoretic assessments in patients achieving VGPR. The prognostic significance of HLC responses might partly depend on the patients' ability to recover their immune system, as determined by normalisation of HLC measurements.
引用
- Michallet M, Chapuis-Cellier C, Dejoie T, et al. Heavy+light chain monitoring correlates with clinical outcome in multiple myeloma patients. Leukemia. 2017. PMID: 28663581. doi:10.1038/leu.2017.209
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。